Tissue Repair Peptide Comparison
Overview
A side-by-side comparison of the two main tissue-repair peptides in this database — BPC-157 and TB-500 (Thymosin Beta-4 / Ac-SDKP) — plus notes on their combination, across chemistry, mechanism, pharmacology, safety and research positioning.
Overview
| Feature | BPC-157 | TB-500 | Combination |
|---|---|---|---|
| Class | Gastric pentadecapeptide | Actin-sequestering peptide | Complementary combination |
| CAS number | 137525-51-2 | 77591-33-4 | — |
| Molecular weight | 1419.5 Da | 500.5 Da (fragment) | — |
| Primary mechanism | NO modulation, VEGF/FGF | Actin sequestration, migration | Dual angiogenic + cytoprotective |
| Main research areas | GI, tendon/ligament, wound | Wound, cardiac, corneal healing | Multi-tissue repair |
Chemical Comparison
| Property | BPC-157 | TB-500 (Ac-SDKP) |
|---|---|---|
| CAS number | 137525-51-2 | 77591-33-4 |
| Molecular formula | C₆₂H₉₈N₁₆O₂₂ | C₂₀H₃₂N₄O₉ |
| Molecular weight | 1419.52 g/mol | 500.52 g/mol |
| Sequence | GEPPPGKPADDAGLV | Ac-SDKP |
| Solubility | Freely soluble (> 50 mg/mL) | Freely soluble (> 50 mg/mL) |
| logP / pI | −2.8 / ≈ 4.2 | −3.1 / ≈ 4.8 |
Mechanism Comparison
| Pathway | BPC-157 | TB-500 |
|---|---|---|
| Angiogenesis | VEGF/FGF via NO | Direct endothelial migration |
| Actin dynamics | Not involved | G-actin sequestration (1:1) |
| Cell migration | Fibroblast / keratinocyte | Endothelial / epithelial |
| Anti-inflammatory | ↓ TNF-α, IL-6; ↑ IL-10 | ↓ NF-κB, TNF-α, IL-1β |
| Collagen / ECM | ↑ Collagen I, III | Modulates MMP activity |
| NO modulation | Direct (eNOS, nNOS) | Indirect |
Pharmacological Comparison
| Parameter | BPC-157 | TB-500 (Ac-SDKP) |
|---|---|---|
| Half-life | ≈ 15 min (plasma) | ≈ 2–6 h |
| Bioavailability (SC) | ≈ 40–60% | ≈ 30–50% |
| Oral bioavailability | Demonstrated in animal models | Poor (GI degradation) |
| Metabolism | Proteolytic | Proteolytic |
| Routes | SC, oral, IP, topical | SC, IM, IV, topical |
| Elimination | Renal (fragments) | Renal (fragments) |
Research Evidence Comparison
A qualitative view of research focus (research context; specific numerical outcomes are not restated as claims):
| Research area | BPC-157 | TB-500 |
|---|---|---|
| GI-mucosa protection | Well studied | Limited |
| Tendon / ligament healing | Well studied | Studied |
| Skin wound healing | Well studied | Well studied |
| Cardiac / corneal repair | Limited | Well studied |
| Human clinical data | Very limited | Early-stage only |
Safety Comparison
Published research observations; both compounds are for research use only, not for human or veterinary use.
| Category | BPC-157 | TB-500 |
|---|---|---|
| Local reactions | Mild | Mild |
| Systemic toxicity | Minimal in animal models | Minimal in animal models |
| Genotoxicity | Negative (Ames) | Negative |
| Immunogenicity | Low | Low |
| Research status | Extensive preclinical | Extensive preclinical; limited clinical |
Dosing Comparison (Research)
Reconstitution-oriented reference ranges from the literature; not human dosing guidance.
| Parameter | BPC-157 | TB-500 | Combination |
|---|---|---|---|
| Typical research dose | ≈ 200–500 µg | ≈ 2.5–5 mg | 250–500 µg + 2.5–5 mg |
| Frequency | 1–2× daily | 1–2× / week | BPC-157 daily; TB-500 ~72 h |
| Route | Subcutaneous | Subcutaneous | Subcutaneous (separate sites) |
Selection Considerations
Choose BPC-157 when
The focus is gastrointestinal-mucosa protection, tendon/ligament healing, fast-acting systemic protection, or an oral route is needed.
Choose TB-500 when
The focus is angiogenesis-driven wound healing, cardiac or corneal repair, or actin-dynamics / cell-migration biology.
Choose the combination when
A broad, multi-tissue regenerative stimulus is the research goal and complementary mechanisms are wanted.
Analytical Method Comparison
| Parameter | BPC-157 | TB-500 |
|---|---|---|
| HPLC column | C18 (4.6 × 250 mm) | C18 (4.6 × 250 mm) |
| Detection | UV 214 nm | UV 214 nm |
| MS ionization | ESI+ | ESI+ |
| Detected mass [M+H]⁺ | ≈ 1420 Da | ≈ 501 Da (fragment) |
Selected References
- Sikiric P, et al. Stable gastric pentadecapeptide BPC-157 (review and preclinical literature).
- Malinda KM, et al. Thymosin beta-4 accelerates wound healing. Journal of Investigative Dermatology, 1999.
- Bock-Marquette I, et al. Thymosin beta-4 promotes cardiac cell survival and repair. Nature, 2004.
Quality & Supply
- Both peptides available research-grade, HPLC-characterized with a Certificate of Analysis per batch
- Identity confirmed by LC-MS
- Research samples through to bulk, with worldwide delivery
- Custom quantities and packaging on request
Need Tissue Repair Peptide Comparison — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
